Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Keryx Biopharmaceuticals nets $65.7mm through FOPO

Executive Summary

Renal therapeutics developer Keryx Biopharmaceuticals Inc. has netted $65.7mm through the follow-on public offering of 8.2mm common shares at $8.49. The company will use the money to build up its pre-launch/launch inventory and future commercialization of Phase III Zenerex, an oral ferric iron-based therapy which binds to phosphate in the GI tract to treat end-stage renal disease patients experiencing hyperphosphatemia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies